Marta Libura

Dr. Marta Libura


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2014 in Leukemia Research
Verified
Journal Article
Closed access
EMEwa Musialik
Ewa Musialik
MBMateusz Bujko
Mateusz Bujko
PKPaulina Kober
Paulina Kober
MGMonika Anna Grygorowicz
Monika Anna Grygorowicz
MLMarta Libura
Marta Libura
JSJanusz Aleksander Siedlecki
Janusz Aleksander Siedlecki

11 May 2021 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MLMarta Libura
Marta Libura
EBEmilia Bialopiotrowicz
Emilia Bialopiotrowicz
SGSebastian Giebel
Sebastian Giebel
AWAgnieszka Wierzbowska
Agnieszka Wierzbowska
GRGail J. Roboz
Gail J. Roboz
OHOlga Haus
Olga Haus
Mutations in isocitrate dehydrogenase 1 and 2 (IDH1/2) genes occur in about 20% patients with acute myeloid leukemia (AML), leading to DNA hypermethylation and epigenetic deregulation. We assessed the prognostic significance of IDH1/2 mutations (IDH1/2+) in 398 AML patients with normal karyotype (NK-AML), treated with daunorubicine + cytarabine (DA), DA + cladribine (DAC), or DA + fludarabine. IDH2 mutation was an independent favorable prognostic factor for 4-year overall survival (OS) in total NK-AML population (p = 0.03, censoring at allotransplant). We next evaluated the effect of addition of cladribine to induction regimen on the patients’ outcome according to IDH1/2 mutation status. In DAC group, 4-year OS was increased in IDH2+ patients, compared to IDH-wild type group (54% vs 33%; p = 0.0087, censoring at allotransplant), while no difference was observed for DA-treated subjects. In multivariate analysis, DAC independently improved the survival of IDH2+ patients (HR = 0.6 [0.37–0.93]; p = 0.024; censored at transplant), indicating that this group specifically benefits from cladribine-containing therapy. In AML cells with R140Q or R172K IDH2 mutations, cladribine restrained mutations-related DNA hypermethylation. Altogether, DAC regimen produces better outcomes in IDH2+ NK-AML patients than DA, and this likely results from the hypomethylating activity of cladribine. Our observations warrant further investigations of induction protocols combining cladribine with IDH1/2 inhibitors in IDH2-mutant.

1 December 2015 in Blood Cells, Molecules, and Diseases
Verified
Journal Article
Closed access
MLMarta Libura
Marta Libura
MPMarta Pawełczyk
Marta Pawełczyk
IFIzabella Florek
Izabella Florek
KMKarolina Matiakowska
Karolina Matiakowska
BJBożena Jaźwiec
Bożena Jaźwiec
OHOlga Haus
Olga Haus

30 June 2012
Verified
Book Chapter
Closed access
PDF file
MLMarta Libura
Marta Libura
AFAgata Filip
Agata Filip
OHOlga Haus
Olga Haus